Open an account

Palvella Therapeutics

PVLA · NASDAQ

$123.92+$0.96 (+0.78%)TodayMarket closed ·
Prev close $122.96

PVLA analyst rating

BuyConsensus of 15 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy1
  • Buy14
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 18 analysts

Average $234.47 (+89.2% upside)

Low
$207.05
Now
$123.92
High
$283.50

Upgrades and downgrades

The latest rating actions, newest first

PVLA analyst upgrades, downgrades and rating actions
FirmDateActionRating
William BlairOct 16, 2026InitiatesOutperform
HC Wainwright & Co.Oct 12, 2026MaintainsBuy
Chardan CapitalSep 21, 2026MaintainsBuy
Stephens & Co.May 21, 2026MaintainsOverweight
Chardan CapitalMay 21, 2026MaintainsBuy
Stephens & Co.May 12, 2026InitiatesOverweight
Chardan CapitalMar 31, 2026MaintainsBuy
HC Wainwright & Co.Mar 24, 2026MaintainsBuy
Chardan CapitalMar 16, 2026MaintainsBuy
MizuhoFeb 25, 2026MaintainsOutperform

The case for and against

Updated Oct 21, 2026

Bull case

Palvella Therapeutics is attractive because its lead asset, QTORIN 3.9% rapamycin anhydrous gel, has already de-risked the core mLM thesis by meeting all SELVA primary and prespecified secondary endpoints, with the rolling NDA completed on Aug 31 and a possible priority review decision expected in 60 days. The company also benefits from a defensible niche: mLM and cVM have no FDA-approved therapies, while prior Phase 2 cVM data were positive and support a Phase 3 start in 4Q26, suggesting multiple shots on goal within a single-segment rare disease platform. Financially, the setup looks scalable rather than speculative, with a planned ~40-rep launch force targeting ~400 centers that cover about half the market, defendable pricing around ~$170K net, and a management team strengthened by key commercial hires.

Bear case

Palvella Therapeutics is burdened by substantial clinical and regulatory uncertainty, as the FDA has already signaled endpoint and bioavailability concerns for mLM, while cVM evidence remains thin after an open-label 16-patient study with no prespecified primary endpoint and declined Breakthrough Therapy designation in July. Its commercial case is also fragile because the company has never generated product revenue, relies on a novel and unproven QTORIN platform, and faces cheaper off-label sirolimus options, uncertain durability, and possible competition from pipeline assets. Financially, it held $250.6M in cash and short-term investments at June 30, 2026, yet still guides to only at least 12 months of runway, with negative free cash flow expected through 2028 and additional dilution likely.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.